Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. Risks are minimal given the promising data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback